<SEC-DOCUMENT>0001193125-26-210298.txt : 20260507
<SEC-HEADER>0001193125-26-210298.hdr.sgml : 20260507
<ACCEPTANCE-DATETIME>20260507070523
ACCESSION NUMBER:		0001193125-26-210298
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260507
DATE AS OF CHANGE:		20260507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Monte Rosa Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001826457
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40522
		FILM NUMBER:		26950803

	BUSINESS ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		STREET 2:		SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
		BUSINESS PHONE:		617-949-2643

	MAIL ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		STREET 2:		SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glue-20260507.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-06T17:31:56.4788+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:glue="http://monterosatx.com/20260507" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_188684d6-4122-41fa-bb61-f292c241c783" name="dei:EntityCentralIndexKey" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9">0001826457</ix:nonNumeric><ix:nonNumeric id="F_578cf942-7b53-4559-8ab2-71eadedadfcf" name="dei:AmendmentFlag" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="glue-20260507.xsd"/></ix:references><ix:resources><xbrli:context id="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826457</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-07</xbrli:startDate><xbrli:endDate>2026-05-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:10pt;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_470c8bbf-174a-4147-977e-84fb47e73718" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Securities Exchange Act of 1934</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3232f00-0016-4392-a0e3-de7133bbb938" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 7, 2026</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3083e34e-1b81-4d0b-8470-fe71293f5eb7" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MONTE ROSA THERAPEUTICS, INC. </span></ix:nonNumeric></span><span style="font-size:24pt;font-family:Times New Roman;"></span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_88cbff7e-a5d1-4a8b-8293-e4a1309ff167" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ef1e673e-aef8-4cbe-b0a2-46335a71b112" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-40522</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d01ea3ed-cc89-4bf3-8af7-8eea072cf0ca" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-3766197</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction<br/>of incorporation)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission<br/>File Number)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58511038-a5fc-4bfd-91bd-bf40471684b3" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">321 Harrison Avenue</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68c25e93-dde7-4c11-b4ec-12b300059a1e" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 900</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed07dfe7-37f9-4793-9491-8b4adba95abf" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d22387e-9ff9-4089-88ab-a8563f5c8f86" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4af6c49-50f6-4458-bc90-b76ecfa004cf" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">02118</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_262db678-c666-498c-a3ce-32c8721b2fce" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb247b18-2d93-46ce-aabd-caec9c571ced" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">949-2643</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_fcae93b0-264d-4d43-9da8-8207e6760dc4" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f7884462-0e05-4655-b555-7c8e519d4b87" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0100c878-9905-445b-9d17-765230e79067" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_74728135-d6eb-46a8-b982-0cac027c20f3" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:41%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:25%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange<br/>on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d2addfeb-9657-448d-a13d-24f111f58788" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_73b146f1-4a27-4a51-afc8-cdf88097486e" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">GLUE</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cfa6cdd5-ff0d-4a71-ad4b-a515442618ca" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_855f20cb-7b5f-48a9-8cc8-0733f2f2ba2a" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91458fcb-b9b1-426f-8662-45cac064440b" contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02. Results of Operations and Financial Condition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information under Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01. Financial Statements and Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:93.28%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="glue-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Monte Rosa Therapeutics, Inc. dated May 7, 2026.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:43%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:3.6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45.4%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Monte Rosa Therapeutics, Inc.</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 7, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Markus Warmuth</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Markus Warmuth</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glue-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-06T17:31:56.5865+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_0.jpg" alt="img106802192_0.jpg" style="width:223px;height:61px;"></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Presented positive interim Phase 1/2 clinical data of GSPT1-directed MGD MRT-2359 in combination with an AR inhibitor in mCRPC patients with AR mutations; initiation of Phase 2 study evaluating MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations planned for Q3 2026</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">of multiple Phase 2 studies in immune-mediated diseases</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">$671 million, expected to support operations into 2029</font></p><p style="margin-left:3.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">BOSTON, Mass., May 7, 2026 </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2013; </font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2026.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,&#x201d; said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. &#x201c;Building on interim clinical data for our NEK7-directed MGD MRT-8102 demonstrating rapid, deep, and durable reductions in systemic inflammation, we expect to read out the GFORCE-1 study in subjects with elevated cardiovascular disease (CVD) risk this year, and to initiate three Phase 2 studies, starting in H2 2026, in diseases driven by the NLRP3/IL-1/IL-6 pathway. We also expect our collaborator Novartis to initiate multiple Phase 2 studies of our VAV1-directed MGD MRT-6160 in immune-mediated diseases this year. In addition, our oncology programs are also progressing rapidly, in particular with a Phase 2 study initiation of MRT-2359 in metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations planned for Q3 2026, following the encouraging Phase 1/2 data we presented at ASCO GU.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">RECENT HIGHLIGHTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">MRT-8102, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome, IL-1, and IL-6</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In January, Monte Rosa announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102. In subjects with elevated CVD risk, after four weeks of MRT-8102 administration, CRP levels decreased by 85%, and 94% of study participants achieved CRP levels below 2 mg/L, a threshold associated with reduced CVD risk. The Company subsequently announced unblinded safety data from the single ascending dose / multiple ascending dose (SAD/MAD) cohorts and 3-month results from the ongoing long-term toxicology study in cynomolgus monkeys support a broad therapeutic index for MRT-8102. </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The ongoing GFORCE-1 study of MRT-8102 in subjects with elevated CVD risk is evaluating multiple dose levels to accelerate development in atherosclerotic cardiovascular disease (ASCVD) with an anticipated readout in H2 2026. </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa expects to initiate multiple Phase 2 studies of MRT-8102 in indications with high unmet need and strong biologic rationale for targeting the NLRP3/IL-1/IL-6 pathway: </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">A study (GFORCE-2) of MRT-8102 in patients with elevated atherosclerotic risk is expected to initiate in H2 2026 to evaluate the effect of MRT-8102 treatment for 12 weeks (plus open-label extension) on CRP levels, as well as effects on liver fat, liver inflammation, and obesity. </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">A study of MRT-8102 in patients with gout flares is expected to initiate in Q4 2026 or Q1 2027.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">A study of MRT-8102 in patients with moderate to severe hidradenitis suppurativa is expected to initiate in H1 2027.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">MRT-6160, VAV1-directed MGD for immune-mediated conditions</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Advancement of MRT-6160 toward multiple Phase 2 studies in immune-mediated diseases is ongoing, in collaboration with Novartis. Results from the Phase 1, single ascending dose / multiple ascending dose (SAD/MAD) study in healthy volunteers (clinicaltrials.gov identifier NCT06597799) support a clear path into anticipated Phase 2 studies and broad potential applications in multiple immune-mediated diseases. </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa has a global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies. Novartis is responsible for conducting and funding Phase 2 studies. Monte Rosa will co-fund any Phase 3 clinical development and will share 30% of any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S., and is also eligible for tiered royalties on ex-U.S. net sales.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">MRT-2359, GSPT1-directed MGD for metastatic CRPC</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In February, Monte Rosa presented additional interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC at the ASCO Genitourinary Cancers Symposium (ASCO GU). MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD. PSA responses in patients with AR mutations expanded to 5 of 5 patients, with a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reductions in size of target lesions. Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions. The combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 AEs. There were no treatment discontinuations due to AEs. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company plans to initiate a Phase 2 study (MODeFIRe-1) in 2026 of up to 25 patients to efficiently assess the efficacy of MRT-2359 in combination with the second-generation AR inhibitor apalutamide in mCRPC patients with AR mutations, with potential to expand the study into additional patient subsets. </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In March, Monte Rosa announced it entered into a supply agreement with Johnson &amp; Johnson to evaluate MRT-2359 in combination with ERLEADA&#174; (apalutamide) for the treatment of patients with mCRPC with androgen receptor (AR) mutations in its planned Phase 2 study.</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cyclin E1 (CCNE1)-directed MGD program for CCNE1-amplified solid tumors</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa presented preclinical data on the potential of its potent and highly selective cyclin E1 (CCNE1)-directed molecular glue degrader, MRT-55811, to treat CCNE1-amplified solid tumors at the American Association for Cancer Research (AACR) Annual Meeting 2026. MRT-55811 induced deep tumor regressions in CCNE1-amplified </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> models of ovarian, breast, and gastric cancers, and demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa expects to submit an IND application for its CCNE1 MGD program in H2 2026. The Company expects to develop this molecule in ovarian cancer and other cancer types driven by CCNE1 amplification. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CDK2-directed MGD program for ER+ breast cancer</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa continues to advance its CDK2-directed MGD program for the treatment of ER+ breast cancer toward clinical development.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Corporate</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In January, Monte Rosa closed an upsized underwritten public offering. Gross proceeds, before deducting underwriting discounts and commissions and offering expenses, were $345 million. </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa continues to progress its collaboration with Novartis to develop novel degraders for immune-mediated diseases and its collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ANTICIPATED UPCOMING MILESTONES AND DEVELOPMENT PRIORITIES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Immunology and Inflammation programs</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Readout of MRT-8102 GFORCE-1 study in subjects with elevated CVD risk anticipated in H2 2026. </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Initiate multiple Phase 2 studies of MRT-8102, including in elevated atherosclerotic risk patients in H2 2026, in gout flare patients in Q4 2026/Q1 2027, and in hidradenitis suppurativa patients in H1 2027.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Submit an IND application for a second-generation NEK7-directed MGD in H2 2026.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of VAV1-directed MGD MRT-6160 in immune-mediated diseases in 2026.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Oncology programs</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Initiate the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Submit an IND application for a cyclin E1-directed MGD in H2 2026.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">FIRST QUARTER 2026 FINANCIAL RESULTS</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Collaboration Revenue: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Collaboration revenue for the first quarter of 2026 was $4.2 million, compared to $84.9 million for the first quarter of 2025. Collaboration revenue represents amounts earned from the Company&#x2019;s collaboration and license agreements with Roche and Novartis.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and Development (R&amp;D) Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D expenses for the first quarter of 2026 were $44.1 million, compared to $32.2 million for the first quarter of 2025. These increases were driven by increased spending during the quarter on our MRT-8102 program and on other development and discovery programs.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and Administrative (G&amp;A) Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">G&amp;A expenses for the first quarter of 2026 were $10.2 million, compared to $8.7 million for the first quarter of 2025. These increases, which include non-cash stock-based compensation, were driven by increased headcount and expenses in support of our growth and operations as a public company.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss for the first quarter of 2026 was $44.5 million, compared to $46.9 million net income for the first quarter of 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash Position and Financial Guidance:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2026, were $671.2 million, compared to cash, cash equivalents, restricted cash, and marketable securities of $382.1 million as of December 31, 2025. The increase of $289.1 million was primarily due to net proceeds from the underwritten public offering in January, partially offset by operational use of cash.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In January 2026, the Company closed an underwritten public equity offering of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$345.0 million aggregate gross proceeds. Aggregate net proceeds from the offering after deducting underwriting discounts and commissions and offering expenses were $323.8 million.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Based on current cash, cash equivalents, restricted cash, and marketable securities, together with the proceeds from the January 2026 offering, the Company expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures into 2029.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Monte Rosa</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa&#x2019;s QuEEN&#153; (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry&#x2019;s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This communication includes express and implied &#x201c;forward-looking statements,&#x201d; including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan,&#x201d; &#x201c;objective,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;ongoing,&#x201d; or the negative of these</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline, our ability to successfully complete research and further development and commercialization of our drug candidates in current or future indications, including the timing and results of our clinical trials and our ability to conduct and complete clinical trials, statements regarding our progress and speed of development of only-in-class and first-in-class molecular glue degrader therapeutics, statements around the Company&#x2019;s QuEEN&#153; discovery engine and the broad potential applications of the platform and the Company&#x2019;s ability to create long-term value through focused pipeline execution and strategic collaborations, as well as to expand the targetable protein space for MGD drug discovery, statements about the Company&#x2019;s view of its potential to rationally design MGDs with unprecedented selectivity, statements about the advancement and timeline of our preclinical and clinical programs, pipeline and the various products therein, including (i) the ongoing development of our VAV1-directed degrader, referred to as MRT-6160, statements related to its clear path into anticipated Phase 2 studies in collaboration with Novartis and our expectations regarding the broad potential applications in multiple immune-mediated diseases, as well as our expectation that our collaborator, Novartis, will initiate multiple Phase 2 studies of VAV1-directed MGD MRT-6160 in immune-mediated diseases in 2026, (ii) the ongoing development and progress of our NEK7-directed MGD, referred to as MRT-8102, including our expectations regarding anticipated readout of data of the GFORCE-1 study in subjects with elevated CVD risk in H2 2026, as well as our plans to target initiation of multiple Phase 2 studies of MRT-8102, including in elevated atherosclerotic risk patients in H2 2026, in gout flare patients in Q4 2026/Q1 2027, and in hidradenitis suppurativa patients in H1 2027, (iii) the ongoing development of a second-generation NEK7-directed MGD and our statements around targeted IND submission in H2 2026, (iv) our ongoing clinical development of MRT-2359, statements relating to our plans to target initiation of the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with the second-generation androgen receptor inhibitor apalutamide in mCRPC in Q3 2026 and the potential to expand the study into additional patient subsets, (v) statements around the progress of both our CDK2 and cyclin E1-directed MGD programs, including statements around the targeted timing of submission of an IND application in H2 2026 for a cyclin E1-directed MGD, and statements regarding the expected potential clinical benefit of MRT-55811 in CCNE1-amplified solid tumors, as well as statements related to the expected potential clinical benefit of any of our candidates, advancement and application of our platform, statements around our ability to capitalize on and potential benefits resulting from our research and translational insights, including announcements related to preclinical programs, as well as our ability to optimize collaborations with industry partners on our development programs, including our collaborations with Novartis and Roche, statements about obligations under our collaboration agreements, expectations around the receipt of any payments under such agreements and the future studies, development and commercialization of various products, statements regarding regulatory filings for our development programs, including the planned timing of such regulatory filings, such as IND applications, and potential review by regulatory authorities, our use of capital, expenses and other financial results in the future, availability of funding for existing programs through multiple anticipated Phase 2 study initiations and clinical data readouts, ability to fund operations and capital expenditures into 2029, as well as our expectations of success for our programs, strength of collaboration relationships and the strength of our financial position, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on March 17, 2026, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:68.86%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.4%;box-sizing:content-box;"></td>
     <td style="width:12.34%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:12.26%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(unaudited)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,859</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,883</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">506,361</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;247,221</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration receivable</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2015;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,609</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,600</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,718</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,481</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">677,547</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393,185</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,409</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,986</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,693</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,386</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,947</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,954</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">832</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736,428</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448,659</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Accounts payable</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                 7,900</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                 3,550</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,594</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,694</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current deferred revenue</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,059</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,571</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of operating lease liability</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,483</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,397</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total current liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,036</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,212</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue, net of current</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,635</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,332</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Defined benefit plan liability</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,260</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,265</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,581</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,794</font></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,512</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215,603</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">Common stock, $0.0001 par value; 500,000,000 shares authorized,        84,321,705 and 65,543,723 shares</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">issued and outstanding as of March 31, 2026 and December 31, 2025, respectively</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;1,048,371</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;714,090</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,746</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,827</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(521,717</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(477,214</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">521,916</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233,056</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736,428</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448,659</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.62%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:16.58%;box-sizing:content-box;"></td>
     <td style="width:2%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:14.8%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:0.7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img106802192_1.jpg" alt="img106802192_1.jpg" style="width:223px;height:61px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.588%;box-sizing:content-box;"></td>
     <td style="width:0.974%;box-sizing:content-box;"></td>
     <td style="width:1.109%;box-sizing:content-box;"></td>
     <td style="width:16.563%;box-sizing:content-box;"></td>
     <td style="width:0.974%;box-sizing:content-box;"></td>
     <td style="width:0.974%;box-sizing:content-box;"></td>
     <td style="width:0.974%;box-sizing:content-box;"></td>
     <td style="width:1.109%;box-sizing:content-box;"></td>
     <td style="width:13.277%;box-sizing:content-box;"></td>
     <td style="width:1.482%;box-sizing:content-box;"></td>
     <td style="width:0.974%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="11" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statement of Operations</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="11" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="11" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(unaudited)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="7" style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended<br>March 31,</font></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Collaboration revenue</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4,210</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">84,929</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">44,069</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">32,190</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10,175</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8,703</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;54,244</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">40,893</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Loss) income from operations</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(50,034</font><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">44,036</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other income:</font></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#caedfb;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5,591</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3,439</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency exchange (loss) gain</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(8</font><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">173</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gain on disposal of property and equipment</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2015;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">59</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total other income</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5,583</font><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3,671</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net (loss) income before income taxes</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(44,451</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">47,707</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax provision</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(52</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(822</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net (loss) income</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(44,503</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">46,885</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Andrew Funderburk</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ir@monterosatx.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cory Tromblee, Scient PR</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">media@monterosatx.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">###</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img106802192_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img106802192_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", ?\# 2(  A$! Q$!_\0
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M^P>4:<)?*M[>,\S'. 3ZDGIZ5T^C_ B6:R275M6,$[C)AMXP=GL6/7\J\O\
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M(^'/^@%IW_@,G^%:)T[:I@<;_P +P\*_\\[_ /[\_P#UZ/\ A>'A7_GG?_\
M?D?XUQ<NEZ>/CV-/%E;_ &+S /L_EC9]P'[O2O9?^$2\.?\ 0"T[_P !D_PJ
MYJG&VCU Y_0?BIX?\1ZS;Z58K=BXGW;3)%A> 2><^U:<?CC2I/&;>%U6X^WK
MG)V?)PN[K]*TK7PYHME<I<VFDV4$R?=DC@56';@@5Y3:_P#)R,O_  /_ -$5
M,8PE>W8#VNBBBL@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***\N^,_B+4=&TFQM-/G, O782R(2'VK@X![=:<8N3L@/4
M:@N+JWM8O,N9HX8\XW2,%&?QHM"39P$\DQKDGZ5SOCWPK+XP\.C3(KA(&\]9
M=[KD< C'ZT)*]F!T4%Q#=0K-!*DL3='1L@]NM3US_@OP])X7\*6>CRSI,]N9
M"9$& =SLW_LU=!2=KZ %%%% !1110 4444 %%%% !1110 4444 %(0""",@T
MM% 'SI\0/#)\-^(Y!"F+*ZS+ 0.%]5_ _IBN4(Q7TEXT\-Q^)?#TUKM7[3&/
M,MW/\+CM]#TKQ?P/X6DU[Q.+>YB9;>T;=< CI@_=/N37NX7%IT6Y;H\3$X1J
MJE'9GH_PJ\+_ -EZ0=5N4Q=7@R@(Y2/M^?6O1:C1%C1410J@8  X J2O&JU'
M4FYOJ>O2IJG!104445F:!1110 4444 %%%% !1110 4444 >&3?\G&#_ *ZK
M_P"BQ7N=>&3?\G&#_KJO_HL5[G6U;[/H 5X+>:K::)\>[W4KZ41V\"NS'_MC
MP![D\5[U7S_JNCPZ[\?VL+E0T#7"O(IZ,J1[L'ZXQ^-%"VM^PCHUUCXC^-/]
M,T2.+1M+8_N7E WN/7D'/X"J.HW_ ,4?!<9U"_N8M4L(S^].U2%'O@ CZU[0
MBK&JHBA548  P *BNHDN+6:&5%>-T*LK#(((Y!I*JKVLK#,7PAXJL_%VAIJ%
MLIC<'9-"3DQOZ?3T-87CKXC)X:GCTG3+?[;K4X 2$<A,],XZGVKC?@I<&RO/
M$<(;]Q$F_:3QE20/TJE\,]1TJ\\6:MXFU^^MX[@MF#[0XR"Q)R,^@&/:K]DE
M)OHA&_#I?Q<U-/M,FKP:?O&X0X3CVQ@X_.H#XT\;^!;R&/Q;:+>Z?*V/M,0&
M1]".,^Q KTC_ (37PS_T'+'_ +^BLKQ'KGA37?#]]IT^KV$@FB8+F4<-CY2/
M<'%2I-NSCIZ#.IT^_MM4L(+ZSE66WG0/&X[@UXOH/Q<U@VNJK>HE_J!EBAT^
MUBCVEF._<3CJ!A?S'K6S\"]3EGT'4M-D<LEI<!H\GHKCH/Q!/XUSWP1TV&Y\
M4ZM?RQJSVL86,D9VEV/(]\*1^-4H*/-?H(Z&QN/BW>7UO<3V]I;VC2*9(_D4
MA,\\$YZ5I^-_B1)HNI)H.A6GV[69,#;C*QD]!@=3[5Z-VKA?#?P]31/%VH>(
M;F^^VW-T7*;X\&,LV>#]./I6:G%N[6PSG(]'^+E\GVB37+>R9N1" G'M]T_S
MJO#X^\6>"M7@LO&EJD]G,<"ZC R!Z@C@X[CK7K4VI6-L2)[VVB(ZAY57^9KS
M7XO:MHFH^#7@AU"SN+N.9'C6.568>N,5<'S.S6@'>:_J;VWA._U2Q=2T=JTT
M+XR#\N0:\PT3XMZ@?"P%Q$NI>(+FZ:*UMH4V_+A<,P';)/UK<T2>2X^ SM(Q
M9ETZ5 3Z $#^58/P)T&!K>_UZ5%>82?9H"1DH  6(^N0/PIQC&,97Z,1=_LO
MXN:BOVIM5M[ M\PMUV<>W0X_.J<'Q!\6^"]4BL?&EGY]K(<"Y11G'J".&^G6
MO::YSQKH,'B/PK?6,L:M)Y;/ Q'*2 94C_/2HC43=I)6&;=I=P7UI#=VTJR0
M3('1U/# ]*\_\:_$J72]5&@>';3[?K#$*W!98R>V!U/\JP?A5XFEM_ASK?FM
MO&E*TL>X]%92<?3(/YU1^$%YHMG_ &CKFM:C;)J4\NU6G<!P#RQY]2:I4N5M
MO6PC631OBY=Q_:7URWM6;YO(^3CV^Z?YU';?$'Q/X/U6'3O&]FK6LIPMY$.@
M]<CAAZ]#7HG_  FOAG_H.6/_ ']%<QX^U;PMX@\&ZA:_VK8RSI&98/W@+!UY
MX]SC'XT1;D[2CH,Z[6M1:W\+:CJ=C(C-'923PN.02$+*?<5SGPK\2:EXI\,7
M%]JLB23I>-$I1-HVA$/3ZDUSG@;4YM0^!^LPS,6-G;74"DG/R^66 _ -C\*O
M? G_ )$B\_["#_\ HN.I<.6,EY@>GUQ?Q-\0ZAX9\)'4-,D2.X\]$RZ[A@GG
MBNTKSCXV_P#(@G_KYC_G44E>:3 LKJ7BW6/AYI=_HAMGU:<!Y3( JE<G.,GZ
M5Y3\2!XT$>G?\)8+4+O?[/Y!7K@9S@_2O;/AU_R3[1?^O?\ J:X'X^?ZG0O^
MNDG\A6U*5JG+8&6(D^,/V>/RO[-V[!MRR=,<=ZZOQ]KVJ>'/ QU"U>-+]6C5
MB5W#)^]Q766?_'E;_P#7-?Y5PWQE_P"2>7/_ %WC_G4*7--)H#=\#ZM=ZYX+
MTW4[YU:YGC+2,J[0<,1T_"N'\0?$[4]0UQ] \%60N[A25>Y*[ER.NT=,#U--
MCU>71OV>H)X'*3R0>3&P.""\A!(_ FM;X-Z%!IW@N+4O+7[5?LSL^.0@8JJY
M]."?QI\JC>374#(&A?%UH_..OP*_7R?D_+.VG:'\2-;T778]!\;V:PO(0L=V
MHP.> 3V(]Q7KE<GXX\$VWC738;>2;[//!)OCG"9('<?0TE-/22 Z*^OK?3K"
M:^N9 EO"AD=_85Y%%XT\<>.[N9?"EK'9:=$VW[1(!G\2>,^P%=OXDT&\E^&-
MWHD,SW5TEH(U<C!DVD'^0Q7$?"GQUHFD^'QH6JRI874$KD-(N%DRV>3V(SCG
MTIPBE%R2NP+3Z)\7+5?.CU^WNF'/E'8,^WW15_P=\2KJ[UB3P_XHM4L=4C!V
MN?D1R!D@@]#CD=C7H-IJVGW^/LE_;3YZ"*56/Z&N5\6?#?3/%>K0ZE<7EQ:3
MQQ^63!M&X9."<CKSBDI*6DU8#MZ***R **** "BBB@ HHHH *KPV=M;22R00
M1QO,VZ1D4 N?4^M6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PR;
M_DXP?]=5_P#18KW.O"Y2/^&C!S_RU7_T6*]TK:M]GT *\3M?^3D9/J__ *(K
MVRO$[7_DY*3ZO_Z(I4?M>@'ME,E_U+_[II],E_U+_P"Z:R0'AGPBA^T7_BN$
M?QPNOYL:R_A3X1T#Q/)JEGK=J\MU;;2@65DP.0W0^N*W/@B0?$7B'_/\9H\4
MZ)JOP]\:MXNT6W:?3)W+7,2#.S/WPWH#U![&NMR]Z44]6([#_A3?@K_H'3?^
M!4G^-,E^$/@>&)Y9;"58T4LS&ZDP .2>M2:=\7_"%[;"6>_>SDQ\T<T3$@_5
M00:Y;QA\3AXCMW\/>$+:YNKB\'EO,$(^4]0HZ\CJ3C K)*HW9W'H=MX&TSPC
M81WK^%95D1V5;@B5GP1G'WOJ:X7X$?\ (2\1_P#;'^<E=[\/?"?_  B'AF.R
ME*M>3,9KEEZ;R ,#V  %<#\"/^0EXC_[8_SDIWTGK?81[/+*D$3RR$!$4LQ/
M8"O#;2X\2_%S6KS[/J3Z9H<#8"H3T.=N0,;F(&>>E>WW=NMU9SVS_=EC*'\1
MBO"/!GB!_A;KFH:%XBM94MYG!6=%STR P]5(/;I4TUHVMP.KA^!VB #[3JNI
MW#=\NH!_2L#XB_#SPSX4\'O>V,,PO&F2-'DF9LYSGCIVKN[CXM>#(;<RKJOG
M'&1''"^X_F /UKS#QQJNK^.=&GU[[*]CH%@0MLDGWIW8X+?YXK2FYN2YGH!V
M_A[_ )(')_UXS?UJ'X$W<<GA.^M0P\V&\+,O^RRK@_H?RJ7P]_R0.3_KQF_K
M7G?@&;7/#.GOXLTVW:]T\3-;7]J@.X( &#_AD\]N_!I\MXR7F!]*52U6[BT_
M2+R\F.(H(7D8^P!-<A9_%_P?<VPFDU"2V?'^JEA8M_XZ"/UKA_%WCR[\?,OA
MGPI9W$D4[#SY6&"X]/\ 97U)ZUC&G)O5#*7PUTZ>Z^'?C(HC%I[?RD '4A&S
M_,5+\*O!?AGQ9H=W+JEJ\UW!/M++,R_*1D< ^QKUKPAX9A\+^%[?201(^"T[
MCH[MU_#M]!7E=[9:M\)/%\^K6=J]UX?NV.]5Z*I.=I/\)!Z'I6W/S<RB_01W
M'_"F_!7_ $#9O_ J3_&H;OX4> K"TDNKJSDB@B7<\C74F%'YU:M/B[X-N;59
MI-3:W8C)BEA?</R!'ZUQ'B[QW<^/L>&/"=G/+'.P\^9AC<H/?^ZO<DU$55;U
M; [*WL/#EA\,_$2^&)!)8R6MRSL)&?Y_*P>6]@*S?@21_P (3>>O]H/_ .BX
MZZSP_P"$K;1/!:>'RV]7A>.=P,;V<'<?U.*\F\+Z[=?"CQ!?:)KUM*;"X?>D
ML:YY' =<\$$8R.HQ[4DN922 ]^KS/XWS)'X%CC8X:6[0*/7&3_(5I3_%[P;#
M;>:NI/*V,^5' ^[]0!^M>7>/-1UCQGHS^)9K=K+0[1UBLXI!\TS,<%_R[].P
M[T4H-33>@SV/X=?\D^T7_KW_ *FN!^/G^IT+_KI)_(5WWPZ_Y)]HO_7O_4UR
M/QOT:[U#0["^M87E2RE8S!!DA6 YQZ<44VE5 ]/L_P#CQM_^N:_RKAOC+_R3
MRY_Z[Q_SJC!\;/"<5M$C+J&50 XA7L/]ZG_%'4(-5^%(U"WW>1<M#+'O&#M;
MD9I1C*,U==0.=U*U>Y_9SLG09\@I*P]O-(_]FKNOA7=1W7PZTKRV!,2O$X'8
MAS_3!_&H? %A!JOPET^PN4WP7%M)$X]BS"O/=)U+5_@_K=QINJ6TMSHES)N2
M:,<'L&7MNQU4^E6_>3BM[B/>ZHZIJMAHMDUYJ%REM;J0ID?ID\"N33XN^#6M
MO..INK8SY1@?=_+'ZUP/B#6]0^+FL6VBZ%:31:5!('FGD&/^!-V&!T'4UG&D
MV_>T0SV*;Q)HUOI4&J3:C!'93_ZJ=CA6^GY5BZOX#\*>+56_FLHV>9=RW-NQ
M0N#T.1U_&D\4>"H=7\!?\(_:$(UO&IMBW3>HXS]>?SKAO!_Q';PA;)X;\76=
MS;26GR13;,_)V!'<#L1GBG%.UX/4"_=_ O3UR^EZU>VLG;> P'Y8/ZUA0^)_
M$_PPUY=)UZX;4=/DCW1G=D[><%2>1R,$&O0)OBSX,BA,BZOYIQD(D$FX_F *
M\VU%;_XQ>+TDTZVEM]*LXC&)Y5X[G)[;B2.!T%:0<G_$V$?0-%%%<PPHHHH
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4PV\,<42C 2-0H'X"IJ*.9O<#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img106802192_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img106802192_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", ?\# 2(  A$! Q$!_\0
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M^P>4:<)?*M[>,\S'. 3ZDGIZ5T^C_ B6:R275M6,$[C)AMXP=GL6/7\J\O\
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M(^'/^@%IW_@,G^%:)T[:I@<;_P +P\*_\\[_ /[\_P#UZ/\ A>'A7_GG?_\
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M\VU%;_XQ>+TDTZVEM]*LXC&)Y5X[G)[;B2.!T%:0<G_$V$?0-%%%<PPHHHH
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4PV\,<42C 2-0H'X"IJ*.9O<#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>glue-20260507.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-06T17:31:56.6470+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://monterosatx.com/20260507" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:glue="http://monterosatx.com/20260507" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="glue-20260507.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 07, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001826457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MONTE ROSA THERAPEUTICS, INC. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-3766197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Harrison Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949-2643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLUE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glue-20260507.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="glue-20260507.htm">glue-20260507.htm</File>
    <File>glue-20260507.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "glue-20260507.htm": {
   "nsprefix": "glue",
   "nsuri": "http://monterosatx.com/20260507",
   "dts": {
    "inline": {
     "local": [
      "glue-20260507.htm"
     ]
    },
    "schema": {
     "local": [
      "glue-20260507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_c73feb4f-e282-40e3-88b3-d8fdab02abd9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glue-20260507.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c73feb4f-e282-40e3-88b3-d8fdab02abd9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glue-20260507.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://monterosatx.com/20260507/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-26-210298-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-210298-xbrl.zip
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MS7JJHORT-XW30$RZE_"0""FTMR5'RX*+JC,6I-.0S 4IBJ_[P:PGQL23XF?
M&(_DSRM:10%[M_7Q+]5Q+,=@%C94@*BA^@1[GJ5B7W,UJADJM1U]"T5D(GKA
M0>\P G#-^P"&A(0#,?[?^;P$S2P;<A^ ]A>U=9][AH^YYD"C"M>QXW@Z9H[/
MB*=HQ&/NUGL%B-S1+,.T][LK0[M]I*;M4-\U-&Q[IHX-TW2Q0SQX5,5,&6$^
M]9='>@#"F F!_#$DYT\:(2KH[=T6$&C/#V:<89^$(%+>RS\W1MU=A77"?9[
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M'8Z6$?*2E-EPF(P.^U^&@[/!X0@=''] AW_V?SLX_G2(^B='1X/1:'!RO-&
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M=[V8S=__L-\=9Y/P_?\#4$L#!!0    ( *HXIUQL72(BH@D  ,QW   1
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M^_.(.KG!P8P$L0L]660?.OTEN3?9#8F0WW0#E7JLD1G?S))Z%8"9/0;,1%+
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M)=#+-\()YO4U:S*4A:]A\QM;QWL</T2&NQR@0CX*=!&/N!G%0;+(U9/,,WR
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M>77+:/5VF9VUOV OE"5%-2+%MJ1N_(@[9#3MM80@();8+_:\!D^W:[1;W:*
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-  , NP   .M/      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>glue-20260507_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glue-20260507.xsd" xlink:type="simple"/>
    <context id="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826457</identifier>
        </entity>
        <period>
            <startDate>2026-05-07</startDate>
            <endDate>2026-05-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_188684d6-4122-41fa-bb61-f292c241c783">0001826457</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_578cf942-7b53-4559-8ab2-71eadedadfcf">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_470c8bbf-174a-4147-977e-84fb47e73718">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_a3232f00-0016-4392-a0e3-de7133bbb938">2026-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_3083e34e-1b81-4d0b-8470-fe71293f5eb7">MONTE ROSA THERAPEUTICS, INC. </dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_88cbff7e-a5d1-4a8b-8293-e4a1309ff167">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_ef1e673e-aef8-4cbe-b0a2-46335a71b112">001-40522</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_d01ea3ed-cc89-4bf3-8af7-8eea072cf0ca">84-3766197</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_58511038-a5fc-4bfd-91bd-bf40471684b3">321 Harrison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_68c25e93-dde7-4c11-b4ec-12b300059a1e">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_ed07dfe7-37f9-4793-9491-8b4adba95abf">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_2d22387e-9ff9-4089-88ab-a8563f5c8f86">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_c4af6c49-50f6-4458-bc90-b76ecfa004cf">02118</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_262db678-c666-498c-a3ce-32c8721b2fce">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_eb247b18-2d93-46ce-aabd-caec9c571ced">949-2643</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_fcae93b0-264d-4d43-9da8-8207e6760dc4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_f7884462-0e05-4655-b555-7c8e519d4b87">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_0100c878-9905-445b-9d17-765230e79067">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_74728135-d6eb-46a8-b982-0cac027c20f3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_d2addfeb-9657-448d-a13d-24f111f58788">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_73b146f1-4a27-4a51-afc8-cdf88097486e">GLUE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_cfa6cdd5-ff0d-4a71-ad4b-a515442618ca">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_855f20cb-7b5f-48a9-8cc8-0733f2f2ba2a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c73feb4f-e282-40e3-88b3-d8fdab02abd9"
      id="F_91458fcb-b9b1-426f-8662-45cac064440b">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
